Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript

Nov 21, 2019 / 03:20PM GMT
Release Date Price: $60.38 (+1.16%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Good afternoon. This is in Eun Yang, biotech analyst with Jefferies based in New York. Our next presenting company is Ionis Pharmaceuticals. As you know, Ionis is a RNA-targeted therapeutics company with a number of pharma partnerships in place and most notable is SPINRAZA partnered with Biogen.

And presenting from Ionis is Brett Monia, who's the Chief Operating Officer, but he will assume the role of CEO in January 2020. So welcome here. Welcome to the Jefferies conference, and we'll hear from Brett.

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, COO, Senior VP of Translational Medicine & Director

Thank you, Eun. And good afternoon, everybody. Thanks for coming. Very pleased here today to provide you an update on Ionis Pharmaceuticals, where we are today and where we believe we're going in the future.

So first, starting with the forward-looking statements. Please look at these statements. They're forward-looking. So Ionis Pharmaceuticals

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot